

1 Title:

2 Vitamin D levels and COVID-19 severe pneumonia: a prospective case-control study

3

4

5 Running title:

6 Vitamin D and COVID-19 severe pneumonia

7

8

9

10 **Authors:**

11 Fortunato José Cardoso, Department of Gastroenterology, Instituto de Medicina

12 Integral Prof. Fernando Figueira (IMIP)

13 Carla Adriane Leal de Araújo, Department of Pediatrics, Instituto de Medicina Integral

14 Prof. Fernando Figueira (IMIP)

15 José Roberto da Silva Junior, Department of Postgraduate, Instituto de Medicina

16 Integral Prof. Fernando Figueira (IMIP)

17 Angélica Guimarães, Department of Pediatrics, Hospital Dom Malan (HDM)

18 Michelle Viana Taveiro, Department of Pediatrics, Universidade do Vale do São

19 Francisco (UNIVASF)

20 José Natal Figueiroa, Department of Biostatistic, Instituto de Medicina Integral Prof.

21 Fernando Figueira (IMIP)

22 João Guilherme Bezerra Alves, Department of Pediatrics, Instituto de Medicina Integral

23 Prof. Fernando Figueira (IMIP)

24

25 **Corresponding author:**

26 João Guilherme Bezerra Alves

27 Department of Pediatrics, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

28 Rua dos Coelhos, 300, Boa Vista, Recife, Pernambuco – Brazil

29 ZIP: 50070-550

30 Phone: +55 (81) 99974-6351

31 e-mail: joaguilherme@imip.org.br

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50 **Abstract**

51 **Introduction:** The hypothesis that a low vitamin D levels is associated with a higher
52 risk for severe COVID-19 has not been completely proven, especially with severe
53 pneumonia. **Objective:** The goal of this study was to confirm the link between vitamin
54 D levels and COVID-19 severe pneumonia. **Methods:** This prospective case-control
55 study involved 307 patients who developed severe SARS-CoV-2 pneumonia and were
56 hospitalized in an intensive care unit. Age- and sex-matched controls (307) were
57 selected from the same population; 307 patients with mild to moderate forms of
58 COVID-19 who were not hospitalized. Vitamin D levels were assessed during the
59 duration of the disease. **Results:** The mean vitamin D level was lower in the severe
60 COVID-19 pneumonia group as compared to the control group; 26.8 ± 7.6 ng/mL vs
61 28.6 ± 7.4 ng/mL, $p < 0.002$. There were more patients with a sufficient level of vitamin D
62 in the control group as compared to the control group; 127 (20.6%) vs 89 (14.5%),
63 $p < 0.001$. Multivariable analysis showed that a deficient vitamin D level was associated
64 with a higher risk for severe COVID-19 pneumonia (OR=3.0; 95% CI: 1.79, 5.10CI),
65 $p < 0.001$. **Conclusion:** A sufficient vitamin D level is linked to a lower risk of COVID-19
66 severe pneumonia.

67 **Keywords:** COVID-19; SARS-CoV-2; severe pneumonia; vitamin D; severe COVID=19

68

69

70

71

72 **Introduction**

73 The COVID-19 pandemic has become a global threat, not only because of its
74 impact on health but also because of the great economic burden it has placed on the
75 lives of the affected populations [1]. Although in the last few months the pandemic has
76 decreased worldwide, a new wave of COVID has arisen in the last few months in some
77 countries with SARS-CoV-2 Omicron subvariants, especially BQ.1, BQ.1, and XBB [2,
78 3].

79 Infection with SARS-CoV-2 is silent or a benign upper respiratory disease in
80 80% of cases and causes pneumonia in 20% of cases [4, 5]. Approximately half of
81 these patients develop hypoxemic pneumonia, requiring hospitalization and,
82 sometimes, UTI admission and mechanical ventilation. Pneumonia represents the
83 typical presentation of COVID-19 and is the main mortality cause [6, 7]. SARS-CoV-2
84 pneumonia can lead to acute hypoxic respiratory failure, multiorgan failure, and death
85 [8, 9]. SARS-CoV-2 leads to diffuse alveolar damage and micro- and macrothrombi in
86 pulmonary arterial vessels, resulting in profound oxygen desaturation and respiratory
87 distress [10].

88 Due to the presence of the vitamin D receptor in various types of cells and
89 tissues, vitamin D has many biologic activities in various organ systems and acts as an
90 immunomodulatory factor in the prevention of respiratory infections [11, 12]. Some
91 studies have reported that vitamin D may be involved both in the SARSCoV-2
92 replication process and in the binding of the virus to the host [13, 14, 15]. COVID-19
93 has been more commonly reported in regions with populations with low vitamin D,
94 including patients with severe COVID-19 disease [16, 17, 18, 19]. However, these
95 studies have demonstrated conflicting results. A recent meta-analysis showed that the

96 evidence of vitamin D protection against hospitalization, ICU admission, and pulmonary
97 involvement is currently inconsistent and insufficient [20]. Another recent systematic
98 review concluded that deficient vitamin D levels were not associated with an increased
99 mortality rate in patients with COVID-19 when the analysis included studies with
100 adjustments for confounders [21]. In conclusion, the relationship between COVID-19
101 and vitamin D has biological plausibility, but the studies available currently are not
102 conclusive [22].

103 The hypothesis that a low vitamin D levels is associated with a higher risk for
104 severe COVID-19 has not been completely proven, especially with severe pneumonia.
105 Based on all this, this case-control study verified the association between vitamin D
106 level and the risk of severe COVID-19 pneumonia.

107 **Subjects and Methods**

108 This prospective matched case-control study was performed in Recife,
109 Northeast, Brazil. Patients were enrolled at the Instituto de Medicina Integral Prof.
110 Fernando Figueira (IMIP), and Hospital Dom Malan (HDM). Case and control patients
111 were selected between April 2020 and February 2022 from patients treated with
112 COVID-19 at IMIP and HDM.

113 This observational study followed the ethical standards of the 1964 Declaration
114 of Helsinki and its later amendments. This study was previously approved by the
115 Research Ethical Committee of IMIP (CAAE: 40857920.0.0000.5201). Written informed
116 consent was previously obtained from each participant.

117 Patients hospitalized in an intensive care unit with COVID-19 severe pneumonia
118 and over the age of 18 who were considered case patients. COVID-19 severe
119 pneumonia was considered according to the following definition: shortness of breath,
120 low SpO₂, and pulmonary alteration on a CT image. A positive reverse transcription

121 polymerase chain reaction (RT-PCR) test of pharyngeal and nasal swab samples was
122 used to confirm the SARS-Cov-2 infection. For every case patient, a patient with mild
123 or moderate COVID-19 was selected as a control, always matched by age (± 5 years)
124 and gender. Controls were selected from the same hospitals.

125 The vitamin D level was assessed using a chemiluminescence-based
126 immunoassay analyzer. Patients were classified according to vitamin D values as
127 deficient (< 20 ng/mL), insufficient (≥ 20 and ≤ 30 ng/mL), and sufficient (> 30 ng/mL).

128 The sample size was determined based on the following information: (1)
129 significance level of 0.05; (2) power=0.8; (3) proportion of those who were exposed to
130 the protection factor (sufficient vitamin D level) versus those who were not exposed
131 (deficient or insufficient vitamin D level); a difference of 12% in the outcome (COVID-19
132 severe pneumonia); the value of the minimum odds ratio to be detected (0.2); and a
133 case-to-control ratio of one case to one control. A total of 614 patients were calculated;

134 Categorical variables are presented as frequencies and percentages, while
135 continuous variables are presented as means and standard deviations (SDs). The
136 demographic and clinical variables of the case and control patients were compared
137 using the chi-square test or Student's t-test. Multivariable logistic regression was used
138 to assess the independent association between vitamin D levels and SARS-CoV-2
139 severe pneumonia after adjustment for categorical and continuous variables. Results
140 were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical
141 analyses were performed using STATA version 12.1 (USA). A p value of 0.05 was
142 considered statistically significant.

143

144 **Results**

145 A total of 314 patients were studied; 307 case patients hospitalized with COVID-
146 19 severe pneumonia, and 307 matched controls for age and gender, all PCR positive
147 for SARS-CoV-2. There was no difference in the mean age (49.2 ± 13.0 years vs.
148 48.7 ± 11.0 years; $p = 0.631$) or gender (307 males vs. 307 females), respectively, in
149 the cases or control patients. Obesity, overweight, systemic hypertension, type 2
150 diabetes, smoking, and drinking habits showed no differences between cases and
151 controls (Table 1).

152 The mean vitamin D level was lower in case patients as compared to control
153 patients, respectively: 26.8 ± 7.6 ng/mL vs. 28.6 ± 7.4 ng/mL, $p < 0.002$. Vitamin D
154 deficiency and insufficiency were more common in the case group ($p < 0.001$) (Table
155 2). Multivariable analysis showed that a low vitamin D level was independently
156 associated with a higher risk for SARS-CoV-2 severe pneumonia, 95% CI (1.38 –
157 3.01), $p < 0.001$ (Table 3).

158

159 Discussion

160 This prospective case-control study showed that a sufficient vitamin D level was
161 associated with a lower risk of SARS-CoV-19 severe pneumonia. Inversely, a deficient
162 or insufficient vitamin D level increased the risk of SARS-CoV-2-related severe
163 pneumonia. Our findings are in agreement with other observational studies that have
164 approached the severity of illness in COVID-19. However, unlike other studies, our
165 severity criterion used in this study was that of severe pneumonia, i.e., admission to an
166 intensive care unit and complaints of shortness of breath, low SpO₂, and pulmonary
167 alteration on a CT image. Nimavat et al. found no statistical difference between the
168 mean vitamin D level among 156 cases and 204 controls ($p = 0.757$), but vitamin D
169 deficiency was observed in 37.1 % of severe pneumonia cases compared to 20 % and

170 10.1 % among mild and moderate cases, respectively [23]. However, only 23 patients
171 were studied with COVID-19 severe pneumonia. Ye et al. also reported a higher
172 percentage of vitamin D deficiency among patients with severe disease as compared to
173 mild/moderate disease, but they studied only 10 patients with COVID-19 severe
174 pneumonia [24]. Israel et al. in a large retrospective case-control study based on an
175 Israeli database, showed a significant association between vitamin D deficiency and
176 the risks of SARS-CoV-2 severe disease [25]. However, they measured vitamin D
177 levels a long time before hospitalization. These findings, however, are not unanimous.
178 Novakovic et al. studied 685 patients hospitalized with COVID-19 and did not find an
179 association between vitamin D level and 30-day mortality [26].

180 Some systematic reviews have also examined the association between vitamin
181 D levels and COVID-19 severity. These reviews tend to converge on an inverse
182 association between vitamin D levels and COVID-19 severity. However, the authors
183 emphasize the need for further studies because of the low or moderate quality of the
184 studies. Pereira et al. [27] concluded that vitamin D deficiency was not associated with
185 a higher chance of infection by COVID-19 (OR = 1.35; 95% CI = 0.80-1.88), but that
186 severe cases of COVID-19 present 64% (OR = 1.64; 95% CI = 1.30-2.09) more vitamin
187 D deficiency compared with mild cases. Ebrahimzadeh et al. [28] found a significant
188 direct association between vitamin D deficiency and an elevated risk of COVID-19 in-
189 hospital mortality. Kazemi et al. [29] concluded that lower vitamin D levels correlated
190 with disease severity and a poor prognosis, but most of the studies were observational
191 and of moderate quality. On the other hand, Al Kiyumi et al. [30] concluded that the
192 evidence of vitamin D deficiency and COVID-19 hospitalization, ICU admission, and
193 pulmonary involvement, was inconsistent and insufficient.

194 It has been hypothesized that there are some potential mechanisms to explain
195 the observed association between vitamin D levels and SARS-CoV-2 infection severity.

196 Vitamin D competes to maintain cell junctions and has protective effects against
197 thrombosis, endothelial dysfunction, and thrombosis. SARS-CoV-2 disrupts cell
198 junction integrity [31]. Vitamin D also enhances cellular innate immunity and interferes
199 with viral replication through the induction of antimicrobial peptides [32]. Vitamin D still
200 promotes the production of antimicrobial and antiviral proteins (β -defensin 2 and
201 cathelicidin), both of which inhibit the replication of SARS-CoV-2 and stimulate the
202 clearance of virus from cells by autophagy [32]. Besides, it has been suggested that
203 vitamin D stimulates ACE2 receptors, which can bind to SARS-CoV-2 and prevent it
204 from attaching to ACE2 receptors and entering the cells [33]. Finally, vitamin D has
205 anti-inflammatory effects, including inhibition of TNF- α (tumor necrosis factor- α) and IL-
206 6 which can help to avoid a cytokine storm and hyper-inflammatory state caused by
207 SARS-CoV-2 and associated with high mortality [33].

208 Our research has strengths and limitations. This case control study had
209 prospective recruitment and contemporaneous control subjects, and only patients with
210 COVID-19 severe pneumonia with intensive care admission were included. We did not
211 identify observational studies exploring this association in tropical regions where
212 people are exposed to sunlight almost all days of the year. Besides, our study included
213 two health reference centers in Pernambuco State, Brazil, and had the sample size
214 calculated. However, our findings must be interpreted with caution because of certain
215 limitations. First, we could not control the vaccine response in case studies or control
216 patients because, until the middle of the study, vaccines for COVID were not yet being
217 applied in Brazil. Second, we did not include cases of death. Our study design included
218 patients in the intensive care unit, and they had to be able to respond to a
219 questionnaire at the time of discharge from the intensive care unit, which made it
220 impossible to study patients who died.

221 This finding emphasizes the protective effects of a sufficient vitamin D level
222 against the risks of COVID-19 severe pneumonia. This result has critical implications

223 for public health, especially considering that, until now, COVID-19 had no specific
224 treatment. Thus, it is mandatory to encourage the general population to keep their
225 vitamin D levels sufficient in their everyday routine to reduce the risk of COVID-19
226 severe pneumonia, the main cause of COVID-19 mortality.

227 **Conclusion**

228 Previous studies have shown that vitamin D levels are associated with the
229 severity of illness and mortality in COVID-19 patients. This study adds that a sufficient
230 vitamin D level offers protection against COVID-19 severe pneumonia hospitalization
231 and admission to the intensive care unit. Further clinical trial studies are needed to
232 confirm these findings of the beneficial effect of vitamin D on COVID-19 severe
233 pneumonia.

234

235

236 **Ethics approval and consent to participate**

237 This study followed the ethical standards of the 1964 Declaration of Helsinki
238 and its later amendments. Written informed consent was obtained previously from each
239 participant. This study was previously approved by the Research Ethical Committee of
240 Instituto de Medicina Integral Prof. Fernando Figueira (IMIP); CAAE (Certificate of
241 Presentation of Ethical Appreciation): 40857920.0.0000.5201.

242

243 **Availability of data and materials**

244 Data are available from the authors upon reasonable request and with permission
245 from the Instituto de Medicina Integral Prof. Frnando Figueira (IMIP) – www.imip.org.br

246 **Competing interests**

247 None declared

248

249 **Funding**

250 CNPq (Brazilian National Council for Scientific and Technological

251 Development), grant number 401907/2020-1.

252

253 **Authors' contributions**

254 JGBA and FJC conceived the study. FJC, CAA, JRSJ, and MRT participated in

255 the data collection. JGBA and JNF analyzed the data. JGBA and FJC wrote the main

256 manuscript text. All authors reviewed the manuscript.

257

258 **Acknowledgments**

259 The authors would like to thank to the CNPq (Brazilian National Council for

260 Scientific and Technological Development), who financed this study, grant number

261 401907/2020-1.

262

263

264

265 **References**

- 266 1 - Naseer S, Khalid S, Parveen S, Abbass K, Song H, Achim MV. COVID-19 outbreak:
267 Impact on global economy. *Front Public Health*. 2023;10:1009393. doi:
268 10.3389/fpubh.2022.1009393.
- 269 2 - Mohsin M, Mahmud S. Omicron SARS-CoV-2 variant of concern: A review on its
270 transmissibility, immune evasion, reinfection, and severity. *Medicine (Baltimore)*.
271 2022;101(19):e29165. doi: 10.1097/MD.00000000000029165.
- 272 3 - Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y. Alarming antibody evasion
273 properties of rising SARS-CoV-2 BQ and XBB subvariants. *Cell*. 2023;186(2):279-
274 286.e8. doi: 10.1016/j.cell.2022.12.018.
- 275 4 – Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi L, Juden-Kelly C, Moghadas SM et al.
276 Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. *Proc*
277 *Natl Acad Sci U S A* 2021; 118(34).
- 278 5 - Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A
279 Narrative Review. *Ann Intern Med* 2020;173(5):362–367
- 280 6 - Budinger GRS, Misharin AV, Ridge KM, Singer BD, Wunderink RG. Distinctive
281 features of severe SARS-CoV-2 pneumonia. *J Clin Invest*. 2021;131(14):e149412. doi:
282 10.1172/JCI149412.
- 283 7 – Ketcham SW, Bolig TC, Molling DJ, Sjoding MW, Flanders SA, Prescott HC.
284 Causes and Circumstances of Death among Patients Hospitalized with COVID-19: A
285 Retrospective Cohort Study. *Ann Am Thorac Soc*. 2021;18(6):1076-1079. doi:
286 10.1513/AnnalsATS.202011-1381RL.
- 287 8 - Santus P, Radovanovic D, Saderi L, Marino P, Cogliati C, Filippis G et al. Severity
288 of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a
289 prospective observational multicentre study. *BMJ Open*. 2020;10(10)
290 doi: 10.1136/bmjopen-2020-043651.

- 291 9 - Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
292 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
293 Review. *JAMA*. 2020;324(8):782-793. doi: 10.1001/jama.2020.12839.
- 294 10 - Carsana L, Sonzogni A, Nasr A, Ross RS, Pellegrinelli A, Zerbi P et al. Pulmonary
295 post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre
296 descriptive study. *Lancet Infect Dis*. 2020;20(10):1135–1140. doi: 10.1016/S1473-
297 3099(20)30434-5.
- 298 11 - Holick MF. Medical progress: vitamin D deficiency. *N Engl J*
299 *Med*. 2007;357(3):266–281. doi: 10.1056/NEJMra070553.
- 300 12 - Rossetti M, Martucci G, Starchl C, Amrein K. Micronutrients in Sepsis and COVID-
301 19: a narrative review on what we have learned and what we want to know in future
302 trials. *Medicina*. 2021;57(5):419. doi: 10.3390/medicina57050419.
- 303 13 - Qayyum S, Mohammad T, Slominski RM, Hassan MI, Tuckey RC, Raman C et al.
304 Vitamin D and lumisterol novel metabolites can inhibit SARS-CoV-2 replication
305 machinery enzymes. *Am J Physiol Endocrinol Metab*. 2021;321(2):E246-E251. doi:
306 10.1152/ajpendo.00174.2021.
- 307 14 - Mansouri A, Kowsar R, Zakariazadeh M, Hakimi H, Miyamoto A. The impact of
308 calcitriol and estradiol on the SARS-CoV-2 biological activity: a molecular modeling
309 approach. *Sci Rep*. 2022 ;12(1):717. doi: 10.1038/s41598-022-04778-y.
- 310 15 - Shalayel MH, Al-Mazaideh GM, Aladaileh SH, Al-Swailmi FK, Al-Thiabat MG.
311 Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding
312 site of SARS-CoV-2 endoribonuclease Nsp15. *Pak J Pharm Sci*. 2020;33(5):2179-
313 2186.
- 314 16 - Rhodes JM, Subramanian S, Laird E, Kenny RA. Editorial: low population mortality
315 from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a

- 316 factor determining severity. *Aliment Pharmacol Ther.* 2020;51(12):1434–1437.
- 317 doi: 10.1111/apt.15777.
- 318 17 - Merzon E, Tworowski D, Gorohovski A, Vinker S, Cohen AG, Green I et al. Low
319 plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection:
320 an Israeli population-based study. *FEBS J.* 2020;13:644.
- 321 18 - Panagiotou G, Tee SA, Ihsan Y, et al. Low serum 25-hydroxyvitamin D (25[OH]D)
322 levels in patients hospitalised with COVID-19 are associated with greater disease
323 severity. *Clin Endocrinol.* 2020 doi: 10.1111/cen.14276.
- 324 19 - D’Avolio A, Avataneo V, Manca A, Lusato J, Nicolo A, Lucchini R et al. 25-
325 hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-
326 CoV-2. *Nutrients.* 2020;12:1359. doi: 10.3390/nu12051359.
- 327 20 - Kazemi A, Mohammadi V, Aghababae SK, et al. Association of Vitamin D Status
328 with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-
329 analysis. *Adv Nutr.* 2021;12(5):1636-1658. doi: 10.1093/advances/nmab012.
- 330 21 - Bignardi PR, de Andrade Castello P, de Matos Aquino B, et al. Is the vitamin D
331 status of patients with COVID-19 associated with reduced mortality? A systematic
332 review and meta-analysis. *Arch Endocrinol Metab.* 2023;67(2):276-288. doi:
333 10.20945/2359-3997000000588.
- 334 22 - Contreras-Bolívar V, García-Fontana B, García-Fontana C, et al. Vitamin D and
335 COVID-19: where are we now? *Postgrad Med.* 2023;135(3):195-207. doi:
336 10.1080/00325481.2021.2017647.
- 337 23 - Nimavat N, Singh S, Singh P, et al. Vitamin D deficiency and COVID-19: A case-
338 control study at a tertiary care hospital in India. *Ann Med Surg (Lond).* 2021; 68:
339 102661. doi: 10.1016/j.amsu.2021.102661

- 340 24 - Ye K, Tang F, Liao X, Deng M, Huang G, Qin Z et al. Does serum vitamin D level
341 affect COVID-19 infection and its severity? - A case-control study. J. Am. Coll. Nutr.
342 2020 doi: 10.1080/07315724.2020.1826005.
- 343 25 - Israel A, Cicurel A, Feldhamer I, Stern F, Dror X, Giveon SM et al.
344 Vitamin D deficiency is associated with higher risks for SARS-CoV-2 infection
345 and COVID-19 severity: a retrospective case-control study. Intern Emerg Med. 2022
346 ;17(4):1053-1063. doi: 10.1007/s11739-021-02902-w.
- 347 26 - Novakovic V, Benfield T, Jørgensen HL, Mitchell NH. Vitamin D as a
348 prognostic biomarker in COVID-19: single-center study and meta-analyses.
349 Scand J Clin Lab Invest. 2023;83(3):173-182. doi:
350 10.1080/00365513.2023.2191333.
- 351 27 - Pereira M, Damascena AD, Azevedo LMG, et al. Vitamin D deficiency aggravates
352 COVID-19: systematic review and meta-analysis. Crit Rev Food Sci Nutr.
353 2022;62(5):1308-1316. doi: 10.1080/10408398.2020.1841090.
- 354 28 - Ebrahimzadeh A, Mohseni S, Narimani B, Ebrahim ZA, Kazemi S, Keshavarz F et
355 al. Association between vitamin D status and risk of covid-19 in-hospital mortality:
356 A systematic review and meta-analysis of observational studies. Crit Rev Food Sci
357 Nutr. 2021;1-11. doi: 10.1080/10408398.2021.2012419.
- 358 29 - Kazemi A, Mohammadi V, Aghababae SK, et al. Association of Vitamin D Status
359 with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-
360 analysis. Adv Nutr. 2021;12(5):1636-1658. doi: 10.1093/advances/nmab012.
- 361 30 - Al Kiyumi MH, Kalra S, Davies JS, Khalan A. The Impact of Vitamin D Deficiency
362 on the Severity of Symptoms and Mortality Rate among Adult Patients with Covid-19:

363 A Systematic Review and Meta-Analysis. *Indian J Endocrinol Metab.* 2021;25(4):261-
364 282. doi: 10.4103/ijem.ijem_115_21.

365 31 - Kumar R, Rathi H, Haq A, Wimalawansa S, Sharma A. Putative roles
366 of vitamin D in modulating immune response and immunopathology associated with
367 COVID-19. *Virus Res.* 2021;292:198235. doi: 10.1016/j.virusres.2020.198235.

368 32 - Gilani SJ, Bin-Jumah MN, Nadeem MS, Kazmi I. Vitamin D attenuates COVID-19
369 complications via modulation of proinflammatory cytokines, antiviral proteins, and
370 autophagy. *Expert Rev Anti Infect Ther.* 2022;20(2):231-241. doi:
371 10.1080/14787210.2021.1941871.

372 33 - Contreras-Bolívar V, García-Fontana B, García-Fontana C, Munoz-Torres M.
373 Vitamin D and COVID-19: where are we now? *Postgrad Med.* 2023;135(3):195-207.
374 doi: 10.1080/00325481.2021.2017647.

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395 Table 1. Some characteristics between case and control groups

396

397 Variable Case (307) Control (307) p

Obesity	41 (13.3%)	27 (8.7%)	0.071
Overweight	179 (58.3%)	158 (51.5%)	0.089
Smoking	23 (7.4%)	19 (6.1%)	0.523
Drinking	146 (47.6%)	142 (46.2%)	0.746
Diabetes Type 2	44 (14.3%)	38 (12.3%)	0.477
Hypertension	110 (35.8%)	117 (38.1%)	0.558

398

399

400 **Table 2.** Univariable analysis of some variables between patients with (Cases) and
 401 without (Controls) severe SARS-CoV-19 pneumonia

Variable	Sample	Case	Control	OR (IC95%)	Valor p
	N	(N = 307) N (%)	(N = 307) N (%)		
Diabetes type 2					0.480
Yes	82	44 (14.3)	38 (12.4)	1.2 (0.74 - 1.88)	
No	532	263 (85.7)	269 (87.6)	1.0	
Smoking					0.538
Yes	42	23 (7.5)	19 (6.2)	1.2 (0.66 - 2.22)	
No	572	284 (92.5)	288 (93.8)	1.0	
Drinking					0.742
Yes	288	146 (47.6)	142 (46.2)	1.1 (0.76 - 1.46)	
No	326	161 (52.4)	165 (53.8)	1.0	
Hipertension					0.566
Yes	227	109 (34.5)	118 (38.4)	0.9 (0.66 - 1.26)	
No	387	198 (64.5)	189 (61.6)	1.0	
Nutritional Status					0.0971
Normal	216	80 (26.1)	136 (44.3)	1.0	
Overweight	337	179 (58.3)	158 (51.5)	1.9 (1.33 – 2.68)	
Obesity	68	41 (13.3)	27 (8.7)	3.4 (3.14 – 8.90)	
Vitamin D level					< 0.001
Insuficient	294	162 (55,1)	132 (44,9)	2.2 (1.51 – 3.45)	< 0.001
Deficient	90	62 (68,9)	28 (31,1)	3.4 (2.08 – 5.75)	< 0.001
Suficient	230	83 (36,1)	147 (63,9)	1.0	

402

403

404 **Table 3.** Multivariable analysis of some variables between patients with (Cases) and
405 without (Controls) severe SARS-CoV-19 pneumonia
406

Variable	Multivariable Model	
	OR (95% CI)	p value
Nutritional Status		
Normal	1.0	0.093
Overweight	1.8 (1.26 – 2.61)	
Obesity	3.3 (2.84 – 8.34)	
Vitamin D Level		<0.001
Insufficient	2.0 (1.38 – 3.01)	
Deficient	3.0 (1.79 – 5.10)	
Sufficient	1.0	

407

408

409

410

411

412